BRIEF—Bayer's Kerendia recommended by ADA

German drug major Bayer’s Kerendia (finerenone), a first-in-class, non-steroidal mineralocorticoid receptor antagonist (ns-MRA), was recommended as part of a comprehensive treatment strategy for patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) in a newly published update to the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease and in a  consensus report jointly issued by KDIGO and the American Diabetes Association (ADA).1

Kerendia was approved by the Food and Drug Administration (FDA) in July 2021 to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular (CV) death, non-fatal myocardial infarction (MI) and hospitalization for heart failure in adult patients with CKD associated with T2D, based on the results of the FIDELIO-DKD pivotal trial.

In September 2022, the FDA approved an updated label for Kerendia to include findings from the Phase III FIGARO-DKD CV outcomes study.